



Anagenesis Biotechnologies Announces Strategic Research Agreement with Boehringer Ingelheim to Discover Drugs for Chronic Muscle Diseases

Illkirch Graffenstaden, France – May 18, 2017 – Anagenesis Biotechnologies announced today a strategic research agreement with Boehringer Ingelheim, which grants Boehringer Ingelheim an exclusive access to Anagenesis' proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for chronic muscle diseases.

The P2MC technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into muscle fibers and adult muscle stem cells, also known as satellite cells. The agreement will support the Boehringer Ingelheim R&D efforts in the discovery of treatments for chronic musculoskeletal diseases such as sarcopenia and cachexia. A High Throughput Screening assay developed by Anagenesis using wild type human muscle progenitors enriched in satellite cells will be used to identify small molecules inducing myogenesis.

“We are excited to partner with Boehringer Ingelheim to advance therapeutic developments for chronic musculoskeletal diseases, where there is a high and growing unmet medical need. We believe our P2MC technology has unique advantages recognized yet again by this new partnership, Boehringer Ingelheim is the third partnership for Anagenesis in the past 18 months, and follows agreements with Ksilink in DMD and CRISPR Therapeutics in cell therapy for muscle diseases.” said Jean-Yves Bonnefoy, PhD, President and Chief Executive Officer of Anagenesis.

About Anagenesis Biotechnologies

Anagenesis Biotechnologies is a private company developing paraxial mesoderm-derived lineages (striated muscle, brown fat, cartilage, bone, dermis & endothelial cells) to generate new treatments against human diseases. Anagenesis' proprietary P2MC technology was developed with the support of AFM-telethon, INSERM Transfert, CNRS and Strasbourg University.

The company was cofounded by Dr. Olivier Pourquié, a worldwide key opinion leader in the field of musculoskeletal development and stem cells. Olivier Pourquié is Professor at the Harvard Medical School and the Brigham and Women's Hospital and a member of the Harvard Stem Cell Institute. Anagenesis Biotechnologies is backed by a solid, experienced team led by its President & CEO, Dr. Jean-Yves Bonnefoy, coming from the Pharma & Biotech industry. Anagenesis Biotechnologies in Illkirch, France, is focusing on High-Troughput and High-Content screens, while its US subsidiary in Boston, MA, Anagenesis Biotherapies Inc., is developing the cell therapy approaches. For more information, please visit www.anagenesis-biotech.com.

MEDIA CONTACTS:

Jean-Yves Bonnefoy

Anagenesis

+33 620 885 092

jybonnefoy@anagenesis-biotech.com